Pirfenidone is a synthetic pyridone compound known for its antifibrotic, anti-inflammatory, and antioxidant properties. It is approved for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic progression of interstitial pneumonia marked by excessive tissue fibrosis. Its precise mechanism of action is not fully known, but it is believed to hinder the generation of transformation growth factor-beta (TGF-β), a substance known to mediate fibrosis. Additionally, Pirfenidone lowers the creation of tumor necrosis factor-alpha (TNF-a) and reduces responsiveness to fibroblast growth factor (FGF)—both crucial factors in the inflammatory and fibrosis process.
Parent: Pirfenidone
Parent: Pirfenidone
Parent: Pirfenidone
Parent: Pirfenidone/ Metacresol
Parent: Pirfenidone
Parent: Pirfenidone
Pirfenidone impurities are unwanted constituent present in Pirfenidone, which may arise during synthesis, storage or handling. They may be related compounds that share a similar structure to Pirfenidone or entirely different compounds. The amount and type of impurities in Pirfenidone can vary due to different factors including the manufacturing process, quality of raw materials used, storage conditions, and degradation over time. The presence and concentration of these impurities are critical as they can affect drug efficacy and safety. However, standards for acceptable levels of these impurities are strictly regulated by international pharmacopeia guidelines.
Pirfenidone is primarily used in the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a severe, chronic, and progressive form of interstitial pneumonia characterized by fibrotic tissue development. The drug may slow the progression of disease, reducing symptoms and improving the quality of life.
While the exact mechanism of action of pirfenidone is not fully understood, it is believed to inhibit the formation of growth factors like TGF-β and TNF-a that mediate fibrosis. Additionally, Pirfenidone reduces responsiveness to fibroblast growth factor (FGF), thereby decreasing inflammation and fibroproliferation.
No, pirfenidone is not a steroid. It is an antifibrotic agent that has anti-inflammatory and antioxidant properties.
Both pirfenidone and nintedanib are used in the treatment of idiopathic pulmonary fibrosis (IPF). However, they differ in their mechanisms of action. While pirfenidone has antifibrotic, anti-inflammatory, and antioxidant effects, nintedanib is a tyrosine-kinase inhibitor that primarily affects vascular endothelial growth factors and fibroblast growth factors. Both drugs have been shown to slow the decline in lung function associated with IPF.
